Thank you, Brian.
prepared more in-depth a quarter. remarks, review as of our June start XXXX. and sheet updated and quarterly a start me our our of today’s brief agenda release what Raul cover in opening our as for the Let with formal as that we overview of guidance revenue a summary After XX, provide remarks. balance press my we will financial you will second financial the condition with for will an of with I during results results financial of XXXX well
open your for then call questions. will the We
Now a review X% reported quarter total revenue revenue with up $XXX.X performance, beginning of in year-over-year. quarter, second million GAAP the second of our we
sales. international driven growth and in Our by total U.S. X% in X% revenue sales was growth growth GAAP
June basis, contributions Our compared rates X.X% in headwind increased the constant total acquisitions organic on an our year to to the XXXX. on in prior revenue X, changes the exchange related currency excluding revenue period year-over-year to growth announced quarter we two and second GAAP the from
in stronger call. one notably the than our we earnings expectations quarter second Our revenue outlined quarter growth that results were
expectations of in in our currency for shared quarter two. to range revenue X% we Specifically, X% constant year-over-year growth organic the
stated, reportable rates a are detailed that constant our in more review a all in and on unless and Note product of are with second basis. growth beginning you of provide revenue now quarter, otherwise currency the each results performance primary with year-over-year the me Let sales our approximated categories.
item non-GAAP from reconciliations included our related release and our website. in to reported the available have We press our presentation on GAAP results
quarter Second segment, quarter. segment. our exceeded growth Endoscopy expected in currency Cardiovascular our the in driven were sales the and growth second X% in while was Endoscopy than by our in growth our Constant Cardiovascular expectations segment softer X% high total revenue end of
representing our driver of peripheral Sales of quarter. again segment products intervention growth increased cardiovascular the XX%, largest this total
total one our our PI products two. sales localization PI the year-over-year, together category, and growth access, total angiography our represented in nearly Within product and products XX% and increased and and sales represented together increased of quarter of embolic radar of drainage XX% roughly growth quarter of XX% PI
I didn’t our SCOUT of proud our in line. be again are out strong of PI our I category. total remiss radar localization largest continued Though would if two, differentiated the to growth the across in PI call performance key highly product products We quarter a number contributor
pleased response mini the been launch. SCOUT as during reflector post the market well full have to We first with our commercial year
key this growth growth contributors Cardiovascular quarter Continuing total OEM to revenue our products XX% a our two on invention segment with sales X% quarter, and of year-over-year, drivers, respectively. and our discussion our of were Cardiac products increasing both
in by our driven sales line and which low our come in single-digit EP products, more XX% than our increased in roughly mid-single both product Sales offset expectations of CI which and growth our intervention sales the of primarily declines hemostasis of year-over-year. strong end products high of the access in CRM products. with our digits, increased angiography
attribute high larger coatings together CRM, the which our OEM year-over-year expectations, and kits to end multiple principally in including growth demand in exceeded customers which we EP, increased XX% Sales improving products, products two. of continued quarter categories our from of
of ability Merit’s growing track driver meet key Importantly, a to demonstrated demand this record is this of growth
of X%, procedural mid in quarter custom we declines driven expected customers increased outside products our U.S. high demand the single-digit to products better CPS was two. customers offset our our This primarily the sales CPS by our upside stronger-than-expected U.S. in notably products of mid-single-digit to Sales which of declines than from solution was which
second in guidance. sales assumed Finally, our and growth Endoscopy which X% our in quarter segment the range increased below we is
work in expected, Endoscopy growth as we qualifications our business constraints to results While pleased the improve experience for to one, continue a to on continued we shortages, supply see disruption vendor. as new and underlying are Endoscopy business quarter material chain trends navigate in
quarter As and discussed for trends growth year endoscopy mid-teens move one in on we as our improvement we call, XXXX. anticipated had business through our the
results business quarter improving guidance softer-than-expected reflects cautiously we mid-teens will two, and see growth updated optimistic the and in of sales endoscopy trends to half are Our that second in we our XXXX. in the continue
basis. summary a to turning performance a brief Now on geographic sales our of
of U.S. better-than-expected $X year-over-year. quarter came million period. of second the the expectations, growth to in U.S. million end growth roughly Our in $X increased Sales in high sales above our approximately the was organic this customers X%
reflects May improving overall second the during in market June. performance growth continued strong our months U.S. of quarter U.S. in and execution business the and Our particularly direct trends the during
International the end better-than-expected the results, our of although Rest sales two. World and in the end high both the exceeding year-over-year, increased in APAC quarter. were of of expectations upper driver quarter at growth expectations EMEA was our the regions primary XX% the of
second was in improving as quarter the China, we growth by into trends our call year-over-year XX% in which sales the increased one APAC continued driven that discussed quarter. March on
overall strategic our The plan. are and throughout overall strong extremely In quarter improving and remain is execution first XXXX. focused the team well but second is summary, of executing the environment half the a pleased remains multiyear and challenging, in with we on
the believe results the our hard second commitment quarter, Growth continue the that for work to we Foundations paying to performance financial respect team’s demonstrate program off. With to in are and our
impressive These Non-GAAP XX.X% first are for XX.X% gross half and of and ’XX. the the margins operating quarter of profitability. respectively, our for improvements XX.X%, and XX.X% and in
to ability and and While our in Growth and related our we for the the our continued program we year period guidance the targets are losing not confident for team’s financial fiscal deliver in X-year focus – Foundation in X-year XX, ended financial XXXX. progress December X of for remain year XXXX
like a Now Raul, call before we for month. a AngioDynamics consideration first take products announced the few of to two of cash On discussing $XXX X, which the million. moments and Biopsy from was would Sealant strategic portfolio the System the dialysis BioSentry, over Tract acquisitions, total last a we to catheter announced turning of acquisitions, the time June I
assets growing Surfacer these foundations in the WRAPSODY Graft markets offering expands includes HeRO which Acquiring strengthens our the dialysis Catheter System. broadens our device Inside-Out the position It Access and the platforms. dialysis our Endoprosthesis, and therapeutic specialty Cell-Impermeable of biopsy and
We Many infrastructure multibillion-dollar leverage to dialysis patients that by to solutions therapies. this rely market. dialysis more combining in us believe commercial the within portfolio patients on interventional of vital relationships, receive these our to serve allow solutions will our Merit physician
conventional flow a catheter catheter dialysis catheter resistant Endexo with compared acquired the to a in-vitro accumulation Thrombus Technology, formation proprietary noncoated material dialysis DuraMax can dialysis portfolio preventing adequate dialysis treatment. catheters. through The blood BioFlo thrombus innovative more to block includes
market. in incidence biopsy-related Biopsy then BioSentry AngioDynamics strengthens acquired also which, The quarter we lung designed hospitalization portfolio, we position to Sealant life-threatening in extend of patients dialysis can of biopsy. specifically Pneumothorax the biopsy undergoing occurs again, potentially BioSentry our the reduce approximately believe, and to addition complication a is that is In Tract one System, pneumothorax. the
privately of serving XXXX investment consideration an equity XXXX. acquire held the system company the the knows the distributor of Technologies in Access acquisition cash from is Vascular million. completed a to second Catheter for was Surfacer we exclusive $XX.X system Merit and Bluegrass total announced May The agreement an purchase global having that established company as through asset Inside-Out a from in Vascular Bluegrass well
to designed device rightsized chemotherapy. venous venous patients including obstructions, obtain life-saving population and hemodialysis access unique with therapies, with a central is Surfacer to providing access The in this
and objective in with portfolio Importantly, commercial invest these acquisitions of assets from selectively consistent strategic markets to our Vascular our footprint. our are that Bluegrass to expand product key leverage stated existing AngioDynamics
these the financial In we is the of believe compelling. strategic rationale, strong acquisitions addition to profile
these basis earnings We closing add our revenue post our and first accretive an share gross closing. non-GAAP non-GAAP to and non-GAAP net $XX to expect $XX the on non-GAAP margins, we full accretive year per annualized million net per contribute of $XX fiscal year both approximately income full acquisitions non-GAAP and income post to million million approximately be and these to in to second the and to in The continue expect share earnings of XXXX. is integration to underway, in and assets revenue operating
second call our With me of XXXX guidance, to turn the and Raul, we that release. results detailed you today’s Raul? which who review over financial in financial said, quarter let take updated through our press a will